ASX Penny Stock Highlights For May 2025

In This Article:

The Australian stock market recently experienced a downturn, with the ASX200 closing down 0.97% at 8,157 points, and sectors like Energy and Financials leading the decline. Despite these broader market challenges, penny stocks continue to capture investor interest due to their potential for significant returns when backed by solid financials. Although the term 'penny stock' might seem outdated, it still highlights smaller or less-established companies that can offer great value; we've identified three such stocks that stand out for their financial strength and potential growth opportunities.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

CTI Logistics (ASX:CLX)

A$1.75

A$140.95M

★★★★☆☆

Accent Group (ASX:AX1)

A$1.865

A$1.06B

★★★★☆☆

EZZ Life Science Holdings (ASX:EZZ)

A$1.53

A$72.17M

★★★★★★

IVE Group (ASX:IGL)

A$2.65

A$408.58M

★★★★★☆

GTN (ASX:GTN)

A$0.60

A$114.67M

★★★★★★

West African Resources (ASX:WAF)

A$2.28

A$2.6B

★★★★★★

Bisalloy Steel Group (ASX:BIS)

A$3.33

A$158.01M

★★★★★★

Regal Partners (ASX:RPL)

A$2.15

A$722.75M

★★★★★★

Navigator Global Investments (ASX:NGI)

A$1.565

A$766.97M

★★★★★☆

NRW Holdings (ASX:NWH)

A$2.67

A$1.22B

★★★★★☆

Click here to see the full list of 990 stocks from our ASX Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Argenica Therapeutics

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Argenica Therapeutics Limited is an Australian biotechnology company focused on the research and development of neuroprotective therapeutic drugs, with a market cap of A$97.99 million.

Operations: Argenica Therapeutics generates revenue primarily from the research and development of medical device technology, amounting to A$3.08 million.

Market Cap: A$97.99M

Argenica Therapeutics, with a market cap of A$97.99 million, is currently pre-revenue and unprofitable, generating limited revenue from research and development activities. The company recently completed dosing for its Phase 2 clinical trial of ARG-007 in acute ischemic stroke patients, with results expected in Q3 2025. Despite having no debt and sufficient cash runway for over two years if current cash flow trends continue, Argenica faces challenges such as negative return on equity and increasing losses over the past five years. Its board lacks extensive tenure experience, which may impact strategic direction.